Tanaka Ryota, Shiraiwa Ken, Takano Kuniko, Ogata Masao, Honda Shuhei, Yoshida Natsumi, Okuhiro Kazuki, Yoshida Masaki, Narahara Kumiko, Kai Makoto, Tatsuta Ryosuke, Itoh Hiroki
Department of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, Japan.
Department of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, Japan.
Clin Biochem. 2022 Jan;99:87-96. doi: 10.1016/j.clinbiochem.2021.10.010. Epub 2021 Oct 27.
For patients with hematological malignancy, triazole antifungal agents such as fluconazole (FLCZ), itraconazole (ITCZ), voriconazole (VRCZ), posaconazole (PSCZ) and isavuconazole (ISCZ) are often used for prophylaxis of deep mycosis. Since these azoles exhibit large pharmacokinetic variability, dose adjustment by therapeutic drug monitoring is recommended for some azoles. This study aimed to develop and validate a novel method for simultaneous determination of plasma concentrations of FLCZ, ITCZ, VRCZ, PSCZ, ISCZ and ITCZ-OH, an active metabolite of ITCZ, using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS).
DESIGN & METHODS: A high-throughput solid-phase extraction method using 96-well MCX µElution Plate was selected as the pretreatment procedure.
The calibration curves for FLCZ, ITCZ, ITCZ-OH, VRCZ, PSCZ and ISCZ showed good linearity (back-calculation of calibrators: relative error ≤ 15% [LLOQ: ≤ 20%]) over wide ranges of 100-100000, 20-20000, 40-40000, 20-20000, 5-5000 and 50-50000 ng/mL, respectively. The validation results of all six drugs fulfilled the criteria of the guidance for bioanalytical method validation of the US Food and Drug Administration for within-batch and batch-to-batch precision and accuracy. The extraction recovery rates were good at ≥ 74.9%, and almost no matrix effects were found for all the drugs. The trough (10 h post-dose in 1 patient on PSCZ) drug concentrations in patients with hematologic malignancy who received oral FLCZ, ITCZ, VRCZ or PSCZ were quantified using the method developed. The measurements for all samples were within the ranges of the calibration curves, demonstrating the feasibility of clinical application of the novel method.
We have succeeded in developing a novel high-throughput method using UHPLC-MS/MS for simultaneous quantification of plasma concentrations of FLCZ, ITCZ, ITCZ-OH, VRCZ, PSCZ and ISCZ.
对于血液系统恶性肿瘤患者,常使用三唑类抗真菌药物,如氟康唑(FLCZ)、伊曲康唑(ITCZ)、伏立康唑(VRCZ)、泊沙康唑(PSCZ)和艾沙康唑(ISCZ)来预防深部真菌病。由于这些唑类药物表现出较大的药代动力学变异性,因此建议对某些唑类药物通过治疗药物监测进行剂量调整。本研究旨在开发并验证一种使用超高效液相色谱-串联质谱法(UHPLC-MS/MS)同时测定血浆中FLCZ、ITCZ、VRCZ、PSCZ、ISCZ以及ITCZ的活性代谢物ITCZ-OH浓度的新方法。
选用一种使用96孔MCX μElution板的高通量固相萃取方法作为预处理程序。
FLCZ、ITCZ、ITCZ-OH、VRCZ、PSCZ和ISCZ的校准曲线在100 - 100000、20 - 20000、40 - 40000、20 - 20000、5 - 5000和50 - 50000 ng/mL的宽范围内均显示出良好的线性(校准品反算:相对误差≤15% [LLOQ:≤20%])。所有六种药物的验证结果均符合美国食品药品监督管理局生物分析方法验证指南中批内和批间精密度与准确度的标准。提取回收率良好,≥74.9%,并且所有药物几乎均未发现基质效应。使用所开发的方法对接受口服FLCZ、ITCZ、VRCZ或PSCZ的血液系统恶性肿瘤患者的谷浓度(PSCZ治疗的1例患者给药后10小时)进行了定量测定。所有样品的测量值均在校准曲线范围内,证明了该新方法临床应用的可行性。
我们成功开发了一种使用UHPLC-MS/MS的新型高通量方法,用于同时定量血浆中FLCZ、ITCZ、ITCZ-OH、VRCZ、PSCZ和ISCZ的浓度。